Declaration of interests

Eiji Shinozaki received honoraria from Takeda Pharma, Merck, Lily, and Chugai Pharma.

Yoshiaki Nakamura received honoraria from Chugai Pharma, Guardant Health AMEA, and Merck and research funding from Taiho Pharmaceutical (Inst), Guardant Health (Inst), Genomedia (Inst), Chugai Pharma (Inst), Guardant Health (Inst), Seattle Genetics (Inst), and Roche (Inst).

Taito Esaki received honoraria from Lilly, Taiho Pharmaceutical, Daiichi Sankyo, and Chugai Pharma and research funding from Daiichi Sankyo (Inst), MSD (Inst), Novartis (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), Lilly (Inst), Bayer (Inst), Nihon Kayaku (Inst), Amgen Astellas BioPharma (Inst), Parexel (Inst), IQVIA (Inst), Quintiles (Inst), Eisai (Inst), Pfizer (Inst), Chugai Pharma (Inst), Syneos Health (Inst), Asahi Kasei Pharma (Inst), Amgen (Inst), Dainippon Sumitomo (Inst), and Dainippon Sumitomo (Inst).

Hisateru Yasui received honoraria from Taiho Pharmaceutical, Chugai Pharma, Bristol Myers Squibb Japan, Daiichi Sankyo, Lilly, Yakult Honsha, Bayer Yakuhin, Takeda, and Ono Pharmaceutical and research funding from MSD (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), and Daiichi Sankyo (Inst).

Hiroya Taniguchi received honoraria from Bayer, Sanofi, Takeda, Chugai Pharma, Taiho Pharmaceutical, Lilly, Merck Serono, Yakult Honsha, Medical & Biological Laboratories Co., Ltd, Bristol Myers Squibb Japan, MSD K.K., Novartis, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Kayaku, and Ono Yakuhin and research funding from Dainippon Sumitomo Pharma (Inst), Array BioPharma (Inst), MSD Oncology (Inst), Ono Pharmaceutical (Inst), Daiichi Sankyo (Inst), Sysmex (Inst), Novartis (Inst), and Takeda (Inst).

Satake Hironaga received honoraria from Bristol Myers Squibb Co., Ltd., Bayer Co., Ltd., Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., MSD Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd. and Yakult Honsha Co., Ltd. and research funding from Ono Pharmaceutical Co Ltd, Daiichi Sankyo, Taiho Pharmaceutical Co Ltd, and Takeda Pharmaceutical Co., Ltd.

Yu Sunakawa received honoraria from Taiho Pharmaceutical, Chugai Pharma, Takeda, Bayer Yakuhin, Bristol Myers Squibb Japan, Lilly, Merck, Sysmex, MSD K.K., Ono Pharmaceutical, Daiichi Sankyo, Guardant Health, and Incyte, has a consulting/advisory role at Bristol Myers Squibb Japan, MSD K.K., Daiichi Sankyo, and Merck, and received research funding from Taiho Pharmaceutical, Takeda, Chugai Pharma, Lilly, Sanofi, and Otsuka.

Yoshito Komatsu received honoraria from Lilly Japan, Taiho Pharmaceutical, Chugai Pharma, Takeda, Bayer Yakuhin, Bristol Myers Squibb Co, Sanofi/Aventis, Merck, Yakult Honsha, Ono Pharmaceutical, Nipro Corporation, Moroo Co, Asahi Kasei, Mitsubishi Tanabe Pharma, Otsuka, Medical Review Co., Ltd, and Daiichi Sankyo and research funding from MSD K.K., Taiho Pharmaceutical, Yakult Honsha, Bayer Yakuhin, DAIICHI SANKYO CO., Ltd, Ono Pharmaceutical, NanoCarrier, Eisai, Sanofi/Aventis, Sysmex, Shionogi, IQVIA, Parexel International Corporation, Astellas Pharma, Mediscience Planning, Sumitomo Dainippon Pharma Co., Ltd, A2 Healthcare, Incyte, Lilly (Inst), Nipro Corporation (Inst), and BeiGene (Inst).

Yoshinori Kagawa has a consulting/advisory role at Taiho Pharmaceutical, Merck, and Lilly, received speakers’ bureau honoraria from Lilly, Sanofi, Takeda, Merck, Taiho Pharmaceutical, MSD, Chugai Pharma, Yakult Pharmaceutical, Bayer, and Ono Pharmaceutical, and received research funding from Ono Pharmaceutical.

Tadamichi Denda received honoraria from Daiichi Sankyo, Ono Pharmaceutical, and Sysmex and research funding from Ono Pharmaceutical (Inst), Amgen (Inst), MSD, Pfizer, and Bristol Myers Squibb Foundation.

Shiozawa Manabu received honoraria from Lilly, Takeda, Taiho, Ono, Yakult, and Merck.

Taroh Satoh received honoraria: Chugai Pharma, Merck Serono, Bristol Myers Squibb, Takeda, Yakult Honsha, Lilly, Bayer Yakuhin, Ono Pharmaceutical, Merck, Astellas Pharma, Taiho Pharmaceutical, Nihon Kayaku, and Daiichi Sankyo, has a consulting/advisory role at Bayer Yakuhin, Lilly, Ono Pharmaceutical, Takara Bio, Merck Serono, and Nihon Kayaku, and received research funding from Yakult Honsha (Inst), Chugai Pharma (Inst), Ono Pharmaceutical (Inst), Sanofi (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Merck (Inst), Merck Serono (Inst), Gilead Sciences (Inst), Dainippon Sumitomo Pharma (Inst), and IQVIA (Inst).

Tomohiro Nishina received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb Japan, Daiichi Sankyo, and Chugai Pharma and research funding from MSD (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), Daiichi Sankyo/UCB Japan (Inst), Bristol Myers Squibb Japan (Inst), Chugai Pharma (Inst), Taiho Pharmaceutical (Inst), and AstraZeneca (Inst).

Toshihumi Yamaguchi received honoraria from Daiichi Sankyo Company, Limited, Ono Pharmaceutical, Taiho Pharmaceutical, MSD K.K, Takeda, Sumitomo Dainippon Pharma Co., Ltd, Yakult Pharmaceutical, and Lilly and research funding from Chugai Pharma, Taiho Pharmaceutical, and Nippon Kayaku.

Naoki Takahashi received honoraria from Ono Pharmaceutical, Bristol Myers Squibb Japan, and Taiho Pharmaceutical.

Takeshi Kato received honoraria from Chugai Pharma, Ono Pharmaceutical, Takeda, Lilly, and Asahi Kasei and research funding from Chugai Pharma.

Hideaki Bando received honoraria from Taiho, Lilly, and Ono. M.W. Nihon Medi-Physics and a research grant from Ono Pharmaceutical.

Kensei Yamaguchi has a consulting/advisory role at Bristol Myers Squibb Japan and Daiichi Sankyo, received honoraria for a speakers’ bureau from Chugai Pharma, Bristol Myers Squibb Japan, Takeda, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical, Daiichi Sankyo, and Merck, and received research funding from Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Daiichi Sankyo (Inst), Lilly (Inst), Gilead Sciences (Inst), Yakult Honsha (Inst), Chugai Pharma (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), MSD Oncology (Inst), Sanofi (Inst), and Bristol Myers Squibb (Inst).

Takayuki Yoshino received honoraria from Chugai Pharma, Takeda Pharma, Merck, Ono Pharmaceutical, and MSD K.K, consulting fee from Sumitomo Corp, and research funding from MSD (Inst), Daiichi Sankyo Company, Limited (Inst), Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Amgen (Inst), Sanofi (Inst), Pfizer (Inst), Sysmex (Inst), Nippon Boehringer Ingelheim (Inst), Chugai Pharma (Inst), isai (Inst), Bristol Myers Squibb (Inst), Caris MPI (Inst), Exact Sciences (Inst), FALCO biosystems (Inst), Medical & Biological Laboratories (Inst), Merus (Inst), Miyarisan Pharmaceutical (Inst), Molecular Health (Inst), Natera (Inst), Roche Diagnostics (Inst), and Takeda Pharmaceutical (Inst).